logo pharnext gb

  

  • Français (FR)
  • English (UK)
  • Home
  • Company
    • Company Overview
    • Leadership Team
    • Board of Directors
    • Scientific and Clinical Advisors
  • Technology
  • Products
    • R&D Pipeline
    • PXT3003
    • PXT864
  • News
    • Press releases
    • Publications
    • In the press
    • Media contact
  • Investors
    • Welcome
    • Share information
    • Press Releases
    • Financial agenda
    • Contacts investors
    • Presentation
    • Regulated Information
    • Letter to Shareholders
    • Annual General Assembly
  • Press releases
  • Publications
  • In the press
  • Media contact

Press releases

04/19/2018

Pharnext to showcase PLEOTHERAPY™ R&D platform at the Global Orphan Drug Conference

04/17/2018

Pharnext confirms its continued eligibility to the PEA-PME (only available in French)

04/12/2018

Pharnext reports financial results for Year-End 2017

04/11/2018

Pharnext successfully raises €16 million via private placement

03/29/2018

Pharnext to present a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference

02/26/2018

Pharnext to attend Shareholders meetings in Bordeaux and Lyon (only in French)

02/19/2018

Pharnext to attend Shareholders meeting in Paris (only in French)

01/18/2018

PXT3003: Status of ongoing Phase 3 trial to be featured at the Francophone Peripheral Nerve Society conference

01/02/2018

Philippe Chambon joins Pharnext’s Board of Directors

11/29/2017

PXT3003: Successful intermediate analyses for Phase 3 trial in CMT1A

11/02/2017

Pharnext to Attend November Investor Conferences

10/30/2017

PXT864: new synergy data to be presented at CTAD in Boston, USA

10/26/2017

PXT3003: Featured at the Hereditary Neuropathy Foundation (HNF) Annual Patient-Centered Summit

10/19/2017

Pharnext announces first half 2017 results

09/28/2017

Pharnext to present at 4th International Neurotech Investing and Partnering Conference

09/18/2017

Pharnext amends the protocol of the international pivotal Phase 3 trials of PXT3003 for CMT1A

09/13/2017

Pharnext to Present at 7th Annual CEC Capital Summit

09/07/2017

PXT3003: Featured at the AANEM 2017 Annual Meeting

09/06/2017

PXT3003: DSMB recommends continuing the ongoing Phase 3 Trial of PXT3003 for CMT1A

09/05/2017

Pharnext to present at Rodman & Renshaw 19th Annual Global Investment Conference

08/31/2017

Pharnext to hold its first satellite symposium on CMT1A at Neuromuscular Days in Marseille

07/10/2017

PXT864: Data presented at the Alzheimer's Association International Conference 2017

06/27/2017

PXT3003: Status of ongoing Phase 3 trial to be featured at the 2017 Peripheral Nerve Society Meeting

06/20/2017

Pharnext to showcase PLEOTHERAPY™ platform at Drug Repositioning, Repurposing and Rescue Conference

05/10/2017

Strategic partnership with Tasly, a leading Chinese pharmaceutical group

04/26/2017

Pharnext reports year end 2016 financial results

04/11/2017

Pharnext confirms its continued eligibility to the PEA-PME

03/29/2017

Reclassification of historical investor’s shares - Strengthening the position of core shareholders

03/29/2017

PXT864: New synergy data presented at AD/PD™ 2017 Conference in Vienna, Austria

03/16/2017

PXT3003: initiation of Phase 3 extension study PLEO-CMT-FU for CMT1A

Page 1 of 3

  • 1
  • 2
  • 3
  • Contact
  • Site Map
  • Legal Notice
  • Job Opportunities